These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 31659146)
1. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p. Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146 [TBL] [Abstract][Full Text] [Related]
2. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells. Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212 [TBL] [Abstract][Full Text] [Related]
3. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis. Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110 [TBL] [Abstract][Full Text] [Related]
4. Downregulation of long non-coding RNA XIST inhibits cell proliferation, migration, invasion and EMT by regulating miR-212-3p/CBLL1 axis in non-small cell lung cancer cells. Qiu HB; Yang K; Yu HY; Liu M Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8391-8402. PubMed ID: 31646569 [TBL] [Abstract][Full Text] [Related]
5. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis. Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072 [TBL] [Abstract][Full Text] [Related]
6. The malignant property of circHIPK2 for angiogenesis and chemoresistance in non-small cell lung cancer. Ren M; Song X; Niu J; Tang G; Sun Z; Li Y; Kong F Exp Cell Res; 2022 Oct; 419(2):113276. PubMed ID: 35863454 [TBL] [Abstract][Full Text] [Related]
7. Identification of circ_0058357 as a regulator in non-small cell lung cancer cells resistant to cisplatin by miR-361-3p/ABCC1 axis. Chu D; Li P; Li Y; Shi J; Huang S; Jiao P Thorac Cancer; 2021 Nov; 12(21):2894-2906. PubMed ID: 34523261 [TBL] [Abstract][Full Text] [Related]
8. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis. Huang Q; Xing S; Peng A; Yu Z Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841 [TBL] [Abstract][Full Text] [Related]
9. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer. Shen Q; Xu Z; Xu S Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379 [TBL] [Abstract][Full Text] [Related]
10. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis. Wang L; Shang X; Feng Q Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109 [TBL] [Abstract][Full Text] [Related]
11. LncRNA KCNQ1OT1 contributes to the cisplatin resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14 axis. Qiao CY; Qiao TY; Jin H; Liu LL; Zheng MD; Wang ZL Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):200-212. PubMed ID: 31957833 [TBL] [Abstract][Full Text] [Related]
12. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway. Xiao XH; He SY Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431 [TBL] [Abstract][Full Text] [Related]
13. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4. Hu B; Zhang H; Wang Z; Zhang F; Wei H; Li L Cancer Biol Ther; 2017 Dec; 18(12):974-983. PubMed ID: 29020498 [TBL] [Abstract][Full Text] [Related]
14. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway. Xu L; Xu Y; Yang M; Li J; Xu F; Chen BL BMC Pulm Med; 2020 Oct; 20(1):266. PubMed ID: 33059643 [TBL] [Abstract][Full Text] [Related]
15. Circular RNA circ-RNF121 contributes to cisplatin (DDP) resistance of non-small-cell lung cancer cells by regulating the miR-646/SOX4 axis. Liu Y; Zhai R; Hu S; Liu J Anticancer Drugs; 2022 Jan; 33(1):e186-e197. PubMed ID: 34387608 [TBL] [Abstract][Full Text] [Related]
16. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. Cai Y; Dong ZY; Wang JY Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323 [TBL] [Abstract][Full Text] [Related]
17. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9. Liu B; Wang R; Liu H Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989 [TBL] [Abstract][Full Text] [Related]
18. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression. Ju ZS; Sun B; Bao D; Zhang XF Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9465-9472. PubMed ID: 33015788 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line. Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998 [TBL] [Abstract][Full Text] [Related]
20. LncRNA XIST Contributes to Cisplatin Resistance of Lung Cancer Cells by Promoting Cellular Glycolysis through Sponging miR-101-3p. Hua G; Zeng ZL; Shi YT; Chen W; He LF; Zhao GF Pharmacology; 2021; 106(9-10):498-508. PubMed ID: 34352791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]